Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.48 |
| ▸ | FURIN | P09958 | 2/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28179921 | 0.95 | CYP19A1 (0.44) | PARP10CHRNB2CHRNA4HRH1CYP19A1 | |
| SCHEMBL13165443 | 0.93 | CYP19A1 (0.46) | PARP10CHRNB2CHRNA4HRH1CYP19A1 | |
| SCHEMBL20400026 | 0.91 | HRH1 (0.43) | PARP10CHRNB2CHRNA4HRH1ROCK1 | |
| SCHEMBL31540092 | 0.91 | HRH1 (0.43) | PARP10CHRNB2CHRNA4HRH1ROCK1 | |
| SCHEMBL20294737 | 0.83 | FURIN (0.45) | PARP10FURINCHRNB2CHRNA4CYP19A1 | |
| SCHEMBL3116000 | 0.83 | EPHX2 (0.39) | PARP10CHRNB2CHRNA4HRH1ROCK1 | |
| SCHEMBL29435759 | 0.81 | LRRK2 (0.48) | HRH1EPHX2IKBKBLRRK2 | |
| SCHEMBL14654942 | 0.81 | CYP19A1 (0.49) | HRH1CYP19A1EPHX2IKBKB | |
| SCHEMBL14634351 | 0.81 | EPHX2 (0.41) | PARP10HRH1CYP19A1EPHX2IKBKB | |
| SCHEMBL29324903 | 0.81 | EPHX2 (0.41) | PARP10HRH1CYP19A1EPHX2IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114728918-A | RIP1 inhibiting compounds and methods of making and using the same | 里格尔药品股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-9556160-B2 | Guanidine compound | ASTELLAS PHARMA INC. (JP) | 2017-01-31 | — | — | US | disclosed |
| US-20150203480-A1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-07-23 | — | — | US | disclosed |
| US-9051283-B2 | Guanidine compound | ASTELLAS PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20130143860-A1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-06-06 | — | — | US | disclosed |
| US-20120129855-A1 | PHTHALAZINONE DERIVATIVES | MENEAR KEITH ALLAN (GB) | 2012-05-24 | — | — | US | disclosed |
| US-20120129855-A1 | PHTHALAZINONE DERIVATIVES | MENEAR KEITH ALLAN (GB) | 2012-05-24 | — | — | US | disclosed |
| US-20120129855-A1 | PHTHALAZINONE DERIVATIVES | MENEAR KEITH ALLAN (GB) | 2012-05-24 | — | — | US | disclosed |
| US-8129380-B2 | Phthalazinone derivatives | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| US-8129380-B2 | Phthalazinone derivatives | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| US-8129380-B2 | Phthalazinone derivatives | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| EP-2231638-A1 | PHTHALAZINONE DERIVATIVES | AstraZeneca AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| WO-2009093032-A1 | PHTHALAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009093032-A1 | PHTHALAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | CBR1, CBR3, SDHA | PARP10 2119/4885FURIN 1557/4885CHRNB2 2682/4885 |
| US-20130143860-A1 | GUANIDINE COMPOUND | GUCY1A1, VAPA, VAPB | PARP10 2291/4885FURIN 3506/4885CHRNB2 3929/4885 |
| US-20120129855-A1 | PHTHALAZINONE DERIVATIVES | CBR1, CBR3, SDHA | PARP10 2119/4885FURIN 1557/4885CHRNB2 2682/4885 |
| US-20150203480-A1 | GUANIDINE COMPOUND | GUCY1A1, VAPA, VAPB | PARP10 2291/4885FURIN 3506/4885CHRNB2 3929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.